Erectile dysfunction (ED) is a common disease in male populations, and the morbidity is increasing. Currently, sildenafil is the first line oral therapy in the treatment of erectile dysfunction, and widely used by the patients from different areas, who are variable in ages, etiologies and degrees of severity, and by the patients with different diseases such as cardiovascular problems, diabetes mellitus and nephropathy. The drug manifests the effectiveness and well tolerance. In this paper, we review and summarize some relevant articles published to share information with the medical colleagues.